Yeasts encoding tumour antigens in cancer immunotherapy.

Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26

Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res (2008) 1.09

Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother (2013) 0.98

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget (2013) 0.98

Saccharomyces cerevisiae: a versatile eukaryotic system in virology. Microb Cell Fact (2007) 0.93

Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. Vaccine (2011) 0.81

Inducing efficient cross-priming using antigen-coated yeast particles. J Immunother (2008) 0.79

The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells. Cancer Immun (2008) 0.77

Oral application of freeze-dried yeast particles expressing the PCV2b Cap protein on their surface induce protection to subsequent PCV2b challenge in vivo. Vaccine (2015) 0.77

Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis. Vaccine (2014) 0.76

Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania. Hum Vaccin Immunother (2014) 0.75

A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood (2007) 1.66

Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther (2003) 1.46

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine (2006) 1.16

Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res (2013) 1.15

Antisense and RNAi: powerful tools in drug target discovery and validation. Curr Opin Drug Discov Devel (2003) 0.96

Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res (2004) 0.96

Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer Immunol Immunother (2014) 0.93

Strong dependence between functional domains in a dual-function snoRNA infers coupling of rRNA processing and modification events. Nucleic Acids Res (2010) 0.86

Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol Ther (2012) 0.85

Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol (2002) 0.84

Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther (2003) 0.83

Induction of laryngeal cancer cell death by Ent-11-hydroxy-15-oxo-kaur-16-en-19-oic acid. Head Neck (2010) 0.82

Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. Cancer Res (2014) 0.81

Reusing surgical instruments during Mohs micrographic surgery: safe from infection, but not free from risk. Dermatol Online J (2016) 0.75

To cut or not to cut? A review of aesthetic approaches to the facial subcutaneous cyst. J Drugs Dermatol (2013) 0.75